MYCOF News and Press, New Age Brands From 11/09/21

The psychedelics industry has grown tremendously these last few years, offering new opportunities for investors interested in this space. The potential for the substance to revolutionize the field of medicine has prompted a significant increase in the capital being injected into the multib...

Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery pr...

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Mydecine Innovations Group ( NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Sm...

NetworkNewsWire Editorial Coverage : Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in medicine to address some of the most resistant, devastating and expensive conditions know...

Mydecine Innovations (OTCPK:MYCOF) announces the filing of a technology patent that allows for the creation of formulations that utilize nanoemulsion technology to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. The patent will cover formulatio...

DENVER, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addicti...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Founded in 2020 based on delivering to significant unmet need in the mental health and therapeutic tr...

NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Mydecine Innovations Group ( NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands in the InvestorBrandNetw...

NetworkNewsWire Editorial Coverage : There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want ...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, will be participating in the Wonderland: Miami. Hosted by Microdose, the upcoming event is scheduled fo...